Compare Illumina, Inc. (ILMN) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Marsh & McLennan Companies, Inc. — how do they compare? Illumina, Inc. trades at $190.45 (market cap $27.94B), while Marsh & McLennan Companies, Inc. trades at $184.14 (market cap $87.77B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 3.1× Illumina, Inc.'s market cap, and Marsh & McLennan Companies, Inc. pays a 2.17% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | MRSH | |
|---|---|---|
Market Cap | $27.94B | $87.77B |
Sector | Health | Financials |
52-Week High | $194.33 | $211.21 |
52-Week Low | $91.00 | $157.32 |
Enterprise Value | $29.33B | $108.61B |
Dividend Yield | — | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Marsh (MRSH) trades at $181.79, down slightly (-0.21%) on the day. The stock exhibits a bullish technical trend with strong moving average signals, while fundamentals are solid with consistent revenue growth to $26.98B in 2025 and a robust net income margin of 14.26%. Recent news highlights a 10% dividend increase to $0.99 per share and strategic partnerships expanding its advisory business. The company has beaten earnings estimates for the last three consecutive quarters.
The outlook for MRSH is positive, supported by earnings momentum and shareholder returns, though rising operating expenses and a premium valuation (P/E of 22.77) present near-term risks. Analyst consensus is a 'Hold' with a $203.75 price target, suggesting modest upside potential from current levels, but investor sentiment is tempered by cost pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
